Evidence map›Paper›PMID 37435707›Full record

ArticleThe EMBO journal2023

A tale of two inhibitors: diarylquinolines and squaramides.

James Chen, Damian C Ekiert

Abstract readComment
In one paragraph

Article in The EMBO journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

James ChenDepartment of Cell Biology, NYU School of Medicine, New York, NY, USA.ORCID 0000-0002-2311-003X
Damian C EkiertDepartment of Cell Biology, NYU School of Medicine, New York, NY, USA.ORCID 0000-0002-2570-0404

Funding

Structural characterization of MCE transport systems from Mycobacterium tuberculosisR01AI174646 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Gira Bhabha, Damian Ekiert · 2023 to 2026
$3.1M
NIAID NIH HHS R01 AI174646
6 · The paper itself

Abstract

The diarylquinoline bedaquiline (BDQ) is an FDA-approved drug for the treatment of multidrug-resistant tuberculosis that targets the mycobacterial adenosine triphosphate (ATP) synthase, a key enzyme in cellular respiration. In a recent study, Courbon et al (2023) examine the interaction between Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ-876 and the squaramide inhibitor SQ31f, showing that both drugs prevent the rotatory motions needed for enzymatic function.

Indexed as

DiarylquinolinesMycobacterium tuberculosisAdenosine TriphosphateAntitubercular AgentsQuinineAdenosine TriphosphateAntitubercular AgentsDiarylquinolinesQuininesquaramide

Identifiers

PMID37435707
PMCPMC10390866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.